Compare LII & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LII | DVA |
|---|---|---|
| Founded | 1895 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 14.9B |
| IPO Year | 1999 | 2003 |
| Metric | LII | DVA |
|---|---|---|
| Price | $363.31 | $183.22 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 4 |
| Target Price | ★ $566.58 | $156.75 |
| AVG Volume (30 Days) | 439.3K | ★ 602.6K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 1.11 | N/A |
| EPS | 3.35 | ★ 6.86 |
| Revenue | $5,195,300,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $6.85 | $3.85 |
| Revenue Next Year | $5.76 | $3.07 |
| P/E Ratio | $107.27 | ★ $26.63 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $350.22 | $101.00 |
| 52 Week High | $587.27 | $247.49 |
| Indicator | LII | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 46.34 |
| Support Level | $350.22 | $173.99 |
| Resistance Level | $396.21 | $202.63 |
| Average True Range (ATR) | 10.70 | 5.25 |
| MACD | 1.88 | 1.63 |
| Stochastic Oscillator | 29.59 | 40.78 |
Lennox manufactures and distributes heating, ventilating, air conditioning, and refrigeration products for the North American replacement (75% of sales) and new construction (25% of sales) markets. Residential HVAC (home comfort solutions) accounts for 67% of sales and commercial HVAC (building climate solutions) accounts for the remaining 33% of sales. Lennox's commercial exposure is what its peers refer to as residential and light commercial, and lacks the scale and complexity of what is referred to as an applied solution. The company goes to market with multiple brands, but Lennox is its flagship HVAC brand.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.